Neogen Corporation SEC filings document material events for an operating company focused on food safety and animal safety products. Recent 8-K filings cover quarterly results and financial condition, Regulation FD disclosures related to Petrifilm manufacturing validation, and exhibits containing earnings releases and business updates.
The company’s filings also record governance and leadership matters, including executive appointments and departures, compensatory arrangements, board committee assignments, annual meeting voting results, executive compensation votes, and auditor ratification. These disclosures provide formal records of Neogen’s public-company reporting, operating updates, governance structure and shareholder matters.
NEOG CEO and director Mikheal Nassif reported a purchase of 505 common shares on October 9, 2026, at $11.95 per share. The shares were held indirectly by his son, and Nassif disclaimed beneficial ownership. The reported post-transaction position for the indirect holding was 1,579 shares. No Rule 10b5-1 plan is reported.
Neogen Corporation (NEOG) reported fiscal 2027 first-quarter revenue of $222.8 million, versus $209.2 million a year earlier, up 6.5%. Gross profit was $105.5 million, compared with $95.0 million, and gross margin was 47.4%, versus 45.4%. Net loss was $11.9 million, or $0.05 per share, compared with net income of $36.3 million, or $0.17 per share; the prior-year period included a $76.4 million gain on the sale of the Cleaners and Disinfectants business. Operating loss was $1.8 million, versus $16.1 million, and operating cash flow was $12.9 million, compared with $10.8 million.
Cash and cash equivalents were $172.0 million as of August 31, 2026. Neogen has a definitive agreement to sell its Genomics business to Zoetis for $160.0 million, subject to customary closing conditions and regulatory approvals; Australian and New Zealand reviews entered a second phase and are expected to conclude by the end of December 2026. A voluntary recall affects approximately 133,000 unexpired units, with full refunds offered. The FDA issued a Warning Letter on September 23, 2026, after inspection of the contract manufacturer’s facility and testing showed microbiological contamination. Neogen prepaid $20.0 million on its term loan in June 2026 and a further $10.0 million in September 2026; no required principal payments are due until the third quarter of fiscal 2029.
Neogen Corporation reported the results of its October 1, 2026 annual meeting, where 176,180,487 of the 218,106,005 shares outstanding and entitled to vote were present and voted. The listed director nominees received 146,152,766 votes for Aashima Gupta, 155,080,607 for Raphael A. Rodriguez, and 154,950,353 for Catherine E. Woteki, Ph.D. Shareholders approved named executive officer compensation on an advisory basis, ratified BDO USA, P.C. as auditor for the fiscal year ending May 31, 2027, approved the amended and restated Omnibus Incentive Plan, and approved an Employee Stock Purchase Plan amendment to increase shares available for issuance. Chief Financial Officer R. Bryan Riggsbee signed the report.
NEOGEN CORP (NEOG) reported fiscal 2027 first-quarter revenue of $222.8 million, up 6.5% from $209.2 million; core revenue growth was 8.1%. Food Safety revenue rose 7.4% to $163.2 million, while Animal Safety revenue rose 4.2% to $59.6 million. GAAP net loss was $11.9 million, or $0.05 per diluted share, versus $36.3 million net income a year earlier, driven primarily by a non-cash gain on a business divestiture. Adjusted net income was $17.5 million and Adjusted EBITDA was $41.6 million, compared with $9.5 million and $35.5 million.
Operating cash flow was $12.9 million and free cash flow was $4.7 million. Neogen raised fiscal 2027 guidance to revenue of $885 million to $890 million and Adjusted EBITDA of $181 million to $183 million. Its planned multi-quarter Petrifilm manufacturing transition to its Lansing site remains on track to begin in November 2026. Neogen continues to work toward completing the previously announced sale of its global Genomics business to Zoetis, subject to customary closing conditions and regulatory reviews expected to conclude by the end of December 2026. It also announced a strategic collaboration and equity investment in Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection.
Neogen Corp. (NEOG) director Catherine E. Woteki received awards on October 1, 2026, consisting of options covering 20,558 common shares at a $12.24 exercise price and 9,804 restricted stock units. The options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants. Her reported restricted stock unit holdings after the award were 28,921.
NEOGEN CORP (NEOG) director Andrea F. Wainer received awards on October 1, 2026, including options covering 20,558 common shares at an exercise price of $12.24 per share, and 9,804 restricted stock units. The options expire October 1, 2036. Both awards vest in equal annual installments on each of the first three anniversary dates of the grants. Her reported post-transaction positions were 20,558 options and 11,834 restricted stock units.
Neogen Corp. (NEOG) director Rafael A. Rodriguez received an award of rights to buy 20,558 common shares at an exercise price of $12.24, along with 9,804 restricted stock units, on October 1, 2026. The reported holdings after the awards were 20,558 rights to buy common stock and 30,625 restricted stock units. Both awards vest in equal annual installments on each of the first three anniversary dates of the grants; the rights to buy common stock expire October 1, 2036.
Avi Pelossof, a director of NEOGEN Corp., received an award of options covering 20,558 common shares at a $12.24 exercise price and 9,804 restricted stock units on October 1, 2026. His reported direct positions after the awards were 20,558 options and 9,804 restricted stock units. Both awards vest in equal annual installments on each of the first three grant anniversaries; the options expire October 1, 2036.
NEOGEN Corp (NEOG) director Aashima Gupta received two awards on October 1, 2026: 20,558 options to buy common stock, with a $12.24 exercise price, and 9,804 restricted stock units. Both awards vest in equal annual installments on each of the first three grant anniversaries. The options expire October 1, 2036. Following the RSU award, her reported shares were 37,594.
Neogen Corp. (NEOG) director Ronald D. Green reported equity awards dated October 1, 2026: 20,558 options to buy common stock and 9,804 restricted stock units (RSUs). The options carry a $12.24 exercise price and expire October 1, 2036. Green's reported direct RSU holdings after the award were 28,458. No Rule 10b5-1 plan is reported.